• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Introduction to H-DL-Abu-OH-d (CAS No. 350820-17-6)

H-DL-Abu-OH-d (CAS No. 350820-17-6) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as H-DL-Aminobutyric acid hydroxylamine, is a derivative of aminobutyric acid and has been extensively studied for its potential therapeutic applications. In this article, we will delve into the chemical properties, biological activities, and recent research findings related to H-DL-Abu-OH-d.

Chemical Properties: H-DL-Abu-OH-d is a white crystalline solid with a molecular formula of C5H11NO3. Its molecular weight is approximately 133.14 g/mol. The compound exhibits good solubility in water and polar organic solvents, making it suitable for various experimental and pharmaceutical applications. The presence of both amino and hydroxyl groups in its structure confers unique chemical reactivity and biological activity.

Biological Activities: Recent studies have highlighted the potential of H-DL-Abu-OH-d in modulating various biological processes. One of the key areas of interest is its role in neurotransmission. Research has shown that H-DL-Abu-OH-d can interact with GABA receptors, which are crucial for inhibitory neurotransmission in the central nervous system. This interaction has led to investigations into its potential as an anxiolytic and anticonvulsant agent.

In addition to its effects on the nervous system, H-DL-Abu-OH-d has been explored for its anti-inflammatory properties. Studies have demonstrated that it can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, suggesting its potential use in treating inflammatory diseases. These findings have opened new avenues for drug development targeting chronic inflammation.

Clinical Applications: The therapeutic potential of H-DL-Abu-OH-d has been evaluated in several preclinical studies. Animal models have shown promising results in reducing anxiety-like behaviors and seizure activity, supporting its potential as a novel anxiolytic and anticonvulsant drug candidate. Furthermore, preliminary clinical trials are underway to assess its safety and efficacy in human subjects.

Mechanisms of Action: The biological activities of H-DL-Abu-OH-d are attributed to its ability to modulate specific receptors and signaling pathways. Its interaction with GABA receptors is thought to enhance inhibitory neurotransmission, leading to reduced neuronal excitability and anxiety-like behaviors. Additionally, its anti-inflammatory effects may be mediated through the inhibition of inflammatory signaling cascades, such as the NF-κB pathway.

Current Research Trends: The ongoing research on H-DL-Abu-OH-d is focused on elucidating its detailed mechanisms of action and optimizing its pharmacological properties for clinical use. Advanced techniques such as molecular docking studies and in silico simulations are being employed to understand its binding interactions with target proteins. These efforts aim to improve the selectivity and potency of the compound while minimizing potential side effects.

Safety and Toxicology: Safety assessments are a critical aspect of drug development, and extensive toxicological studies have been conducted on H-DL-Abu-OH-d. These studies have shown that the compound exhibits low toxicity at therapeutic doses, with no significant adverse effects observed in animal models. However, further investigations are necessary to ensure its safety in human subjects.

FUTURE DIRECTIONS: The future prospects for H-DL-Abu-OH-d are promising, with ongoing research aimed at expanding its therapeutic applications. Potential areas of exploration include neurodegenerative diseases, chronic pain management, and autoimmune disorders. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the development of this compound into a viable therapeutic option.

In conclusion, H-DL-Abu-OH-d (CAS No. 350820-17-6) is a versatile compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical properties and biological activities make it an attractive candidate for further investigation and development as a novel therapeutic agent.

• 2835-81-6(H-DL-Abu-OH)
• 5959-29-5((S)-2-Aminobutanoic acid hydrochloride)
• 80-60-4(2-Aminobutyric acid)
• 119736-88-8(L-Homoserine)
• 6027-21-0(D-Homoserine)
• 1492-24-6(L-Aminobutyric Acid)
• 672-15-1(L-Homoserine)
• 1927-25-9(2-amino-4-hydroxybutanoic acid)
• 2623-91-8((R)-2-Aminobutyric Acid)
• 498-19-1(tert-butyl-m-xylene)